An Exploratory Clinical Study Evaluating the Safety, Tolerance, Immune Response, and Initial Efficacy of Autologous Tumor Infiltrating Lymphocytes (TILs) LM103 Injection in Patients With Advanced Solid Tumors
Latest Information Update: 04 Aug 2023
At a glance
- Drugs LM 103 (Primary) ; Cyclophosphamide; Fludarabine; Interleukin-2
- Indications Cervical cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Suzhou BlueHorse Therapeutics
Most Recent Events
- 04 Aug 2023 New trial record